← All trials
NCT05507970
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 29, 2022
- Primary completion
- Dec 23, 2022
- Completion date
- Dec 23, 2022
- First posted
- Aug 19, 2022
- Last posted
- Nov 8, 2022
- Enrollment
- 72
- Arms / groups
- 9 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Medicines for Malaria VentureLead sponsor
- Banook GroupCollaborator
- GlaxoSmithKlineCollaborator
- QuotientCollaborator
- Swiss BioQuant A.G., SwitzerlandCollaborator
- The Doctors Laboratory LtdCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.